17:45:28 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom utveckling av analytiska program. Produktportföljen är bred och inkluderar exempelvis program för intern uppföljning, process- samt systemhantering. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster inom arbetsområdet. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Magle Chemoswed har sitt huvudkontor i Malmö.

Kalender

2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-12-14 Extra Bolagsstämma 2021
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-14 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Extra Bolagsstämma 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-14 Kvartalsrapport 2020-Q2
2022-05-13 08:00:00

The Magle Group today announces that it will commence its post market clinical study in collaboration with the University of Heidelberg, Medical Faculty a world leading center in pancreatic surgery.

SmartPAN® is a patented first-in-class medical device developed jointly with the University of Heidelberg and Magle Chemoswed AB. SmartPAN® is based on the patented bio-compatible and bio-degradable microsphere technology (DSM) owned by Magle Chemoswed.
 
Postoperative pancreatic fistula (POPF) is a common and potentially life-threatening complication after pancreatic surgery. POPF can develop due to leaking pancreatic fluid. SmartPAN® acts as an intraoperative indicator of leakage by providing a near-immediate and accurate colour indication when in contact with the pancreatic fluid. SmartPAN® provides a less complicated approach to identifying and localising pancreatic leaks that benefits patient outcomes.
 
"The start-up of this PMCF study is a positive step forwards for SmartPAN® and gets us closer to benefitting patients through the use of SmartPAN®," said Bodil Gesslein, Project and Clinical Manager.
 
"We are very happy to perform a stage I first-in-human study according to IDEAL recommendations to evaluate the innovative SmartPAN® leakage indicator with the support of Magle at our study center in Heidelberg” said Thomas Pausch, assistant principle investigator from the Heidelberg trial team.

"We are all very excited to start this PMCF study with the results expected at this year's tail end. Our sponsoring of this study is further evidence of our commitment to clinical and scientific robustness of our DSM products," said Justin Pierce, CEO of Magle Group.